Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

270 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial.
Provencio M, Nadal E, Insa A, García-Campelo MR, Casal-Rubio J, Dómine M, Majem M, Rodríguez-Abreu D, Martínez-Martí A, De Castro Carpeño J, Cobo M, López Vivanco G, Del Barco E, Bernabé Caro R, Viñolas N, Barneto Aranda I, Viteri S, Pereira E, Royuela A, Casarrubios M, Salas Antón C, Parra ER, Wistuba I, Calvo V, Laza-Briviesca R, Romero A, Massuti B, Cruz-Bermúdez A. Provencio M, et al. Among authors: nadal e. Lancet Oncol. 2020 Nov;21(11):1413-1422. doi: 10.1016/S1470-2045(20)30453-8. Epub 2020 Sep 24. Lancet Oncol. 2020. PMID: 32979984 Clinical Trial.
Phase I study of concurrent chemoradiation with pemetrexed and cisplatin followed by consolidation pemetrexed for patients with unresectable stage III non-small cell lung cancer.
Cardenal F, Arnaiz MD, Morán T, Jové J, Nadal E, Porta R, Solé JM, Brao I, Palmero R, Fuentes R, Núñez I, Caveda E, Cassinello A. Cardenal F, et al. Among authors: nadal e. Lung Cancer. 2011 Oct;74(1):69-74. doi: 10.1016/j.lungcan.2011.01.021. Epub 2011 Feb 24. Lung Cancer. 2011. PMID: 21353323 Clinical Trial.
A prognostic DNA methylation signature for stage I non-small-cell lung cancer.
Sandoval J, Mendez-Gonzalez J, Nadal E, Chen G, Carmona FJ, Sayols S, Moran S, Heyn H, Vizoso M, Gomez A, Sanchez-Cespedes M, Assenov Y, Müller F, Bock C, Taron M, Mora J, Muscarella LA, Liloglou T, Davies M, Pollan M, Pajares MJ, Torre W, Montuenga LM, Brambilla E, Field JK, Roz L, Lo Iacono M, Scagliotti GV, Rosell R, Beer DG, Esteller M. Sandoval J, et al. Among authors: nadal e. J Clin Oncol. 2013 Nov 10;31(32):4140-7. doi: 10.1200/JCO.2012.48.5516. Epub 2013 Sep 30. J Clin Oncol. 2013. PMID: 24081945 Free article.
SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015.
García-Campelo R, Bernabé R, Cobo M, Corral J, Coves J, Dómine M, Nadal E, Rodriguez-Abreu D, Viñolas N, Massuti B. García-Campelo R, et al. Among authors: nadal e. Clin Transl Oncol. 2015 Dec;17(12):1020-9. doi: 10.1007/s12094-015-1455-z. Epub 2015 Dec 21. Clin Transl Oncol. 2015. PMID: 26691657 Free PMC article.
Identification of ALK, ROS1, and RET Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Non-Small-Cell Lung Cancer Patients.
Reguart N, Teixidó C, Giménez-Capitán A, Paré L, Galván P, Viteri S, Rodríguez S, Peg V, Aldeguer E, Viñolas N, Remon J, Karachaliou N, Conde E, Lopez-Rios F, Nadal E, Merkelbach-Bruse S, Büttner R, Rosell R, Molina-Vila MA, Prat A. Reguart N, et al. Among authors: nadal e. Clin Chem. 2017 Mar;63(3):751-760. doi: 10.1373/clinchem.2016.265314. Epub 2017 Jan 10. Clin Chem. 2017. PMID: 28073897
Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies B2M Inactivation Impairing Immunorecognition.
Pereira C, Gimenez-Xavier P, Pros E, Pajares MJ, Moro M, Gomez A, Navarro A, Condom E, Moran S, Gomez-Lopez G, Graña O, Rubio-Camarillo M, Martinez-Martí A, Yokota J, Carretero J, Galbis JM, Nadal E, Pisano D, Sozzi G, Felip E, Montuenga LM, Roz L, Villanueva A, Sanchez-Cespedes M. Pereira C, et al. Among authors: nadal e. Clin Cancer Res. 2017 Jun 15;23(12):3203-3213. doi: 10.1158/1078-0432.CCR-16-1946. Epub 2017 Mar 16. Clin Cancer Res. 2017. PMID: 28302866
Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC).
Martinez-Marti A, Felip E, Matito J, Mereu E, Navarro A, Cedrés S, Pardo N, Martinez de Castro A, Remon J, Miquel JM, Guillaumet-Adkins A, Nadal E, Rodriguez-Esteban G, Arqués O, Fasani R, Nuciforo P, Heyn H, Villanueva A, Palmer HG, Vivancos A. Martinez-Marti A, et al. Among authors: nadal e. Ann Oncol. 2017 Oct 1;28(10):2451-2457. doi: 10.1093/annonc/mdx396. Ann Oncol. 2017. PMID: 28961841 Free PMC article.
Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results.
Reck M, Garon EB, Paz-Ares L, Ponce S, Jaime JC, Juan O, Nadal E, Kiura K, Widau RC, He S, Dalal R, Lee P, Nakagawa K. Reck M, et al. Among authors: nadal e. Clin Lung Cancer. 2018 May;19(3):213-220.e4. doi: 10.1016/j.cllc.2017.11.003. Epub 2017 Nov 21. Clin Lung Cancer. 2018. PMID: 29317191 Free article. Clinical Trial.
Geriatric assessment may help decision-making in elderly patients with inoperable, locally advanced non-small-cell lung cancer.
Antonio M, Saldaña J, Linares J, Ruffinelli JC, Palmero R, Navarro A, Arnaiz MD, Brao I, Aso S, Padrones S, Navarro V, González-Barboteo J, Borràs JM, Cardenal F, Nadal E. Antonio M, et al. Among authors: nadal e. Br J Cancer. 2018 Mar 6;118(5):639-647. doi: 10.1038/bjc.2017.455. Epub 2018 Jan 30. Br J Cancer. 2018. PMID: 29381689 Free PMC article.
270 results